Dr. John Cush RheumNow
10 months 3 weeks ago
Lessons Learned in Neuropsychiatric SLE
Dr. Sheila Reyes, The Philippines, reports highlights from a session on neuropsychiatric systemic lupus erythematosus, presented at the APLAR 2025 Congress in Fukuoka, Japan.
https://t.co/Dh1GQnBhvg https://t.co/wX5FgpIq7C
Dr. John Cush RheumNow
10 months 3 weeks ago
PAH diagnosis and management in the context of CTD ILD
Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue disorders (CTD), affecting about 25% of PAH patients. CTD-PAH is the second most common cause after the idiopathic form. PAH involves high https://t.co/UgsdYWv02S
Dr. John Cush RheumNow
10 months 3 weeks ago
QD Clinic Video: RA and Bronchiectasis
Dr. Jeffrey Sparks, Boston, talks about rheumatoid arthritis and bronchiectasis as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/Y2u3m4rFfj https://t.co/KgrIxXlQo4
Dr. John Cush RheumNow
10 months 3 weeks ago
STOP-RA results published in A&R. 144 at risk, CCP+ pts were enrolled to received HCQ vs PBO for 12 mos, w/ 24 mos F/U. Progression to RA seen in 30.4% on HCQ vs 32.9% on PBO (NS; P=0.52). Also IA, Jt Sxs, severity & adverse events were similar between groups.
Dr. John Cush RheumNow
10 months 3 weeks ago
TNR: Future Treatment of ILD
This Tuesday Night Rheumatology webinar reviewed ACR and EULAR guidelines on interstitial lung disease, with a focus on ‘where are we now and where are we going?’ in regards to treatment strategies and emerging therapies in ILD care. https://t.co/F1fJhWgR5O
Dr. John Cush RheumNow
10 months 3 weeks ago
AbbVie's US patent protection for Rinvoq (upadacitinib) will run till April 2037. SEC filing shows AbbVie has reached an agreement with generic manufacturers challenging Rinvoq patents. UPA is their 2nd leading product with nearly $3.75 billion worldwide sales in 1st 1/2 of
Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of life in RA and PsA, and is now being increasingly adopted not only in SLE research but also in clinical practice. This article reviews key highlights from Dr. Eric Morand’s plenary session lecture on Treat to Target in SLE: Current Evidence and Future Directions, presented during the recent APLAR 2025 Congress.
Dr. John Cush RheumNow
10 months 3 weeks ago
Antifibrotics - A New Class of Therapies in Rheumatology?
Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic https://t.co/IobQagC0ZE
Dr. John Cush RheumNow
10 months 3 weeks ago
9 yr. study of anti-Ro52 & ILD pts -- 1,026 pts 15% Ro52+: interstitial pneumonia w/ autoimmune 48%, CTD-ILD 13%, idiopathic pulm fibrosis 10%, hypersens pneumonitis 6%, idiopathic ILD 24%. Ro52+ were younger w/ more autoimmune dz, +MSA Abs, ILD progression, death, & lung https://t.co/fuFfnaYIRd
Aurelie Najm AurelieRheumo
10 months 3 weeks ago
Flow cytometry on Peripheral blood can help patient stratification in RA
A cluster rich in TEMRA Terminally Differentiated Effector Memory T Cells is associated with response to treatment and therapeutic decision taking into account showed higher remission 39% vs. 24%
Next https://t.co/8ZZ2epf7LK
sheila RHEUMarampa
10 months 3 weeks ago
In #scleroderma pts with cardiac involvement, the presence of ventricular ectopy is assocd w/ ⬆️risk of mortality & SCD.
☝️these arrythmias present late so consider it in pts w/established dse who develop new-onset cardiac symptoms
@RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/MTDfxevqwb
Aurelie Najm AurelieRheumo
10 months 3 weeks ago
2025 Update of EULAR RA management recommandation
Summary slide inspired from Josef Smolen’s presentation
@RheumNow #APLAR25 https://t.co/wRzeX9OIry https://t.co/djrd7O9G9H
sheila RHEUMarampa
10 months 3 weeks ago
Is it #lupus?
Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria
A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔
@RheumNow #APLAR25 https://t.co/xByBkjEr3r
sheila RHEUMarampa
10 months 3 weeks ago
Key takeaways of trabecular bone screening:
📌Complements but doesnt replace BMD/FRAX in fracture risk assessment
📌Dont exclude any lumbar spine unless w/significant change like laminectomy
📌Can use in monitoring untreated pts since TBS declines
@RheumNow #APLAR25 https://t.co/bcN83IDDja
